ExecutiveOrdersEO
EO 14273Executive OrderTrump 47 · R Quiet signal

Executive Order 14273

Lowering Drug Prices by Once Again Putting Americans First

This executive order directs multiple federal agencies to take steps to lower prescription drug prices, primarily by modifying the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act, promoting generic and biosimilar competition, expanding drug importation, increasing transparency in pharmacy benefit manager compensation, and conditioning health center grants on providing discounted insulin and epinephrine to low-income patients.

Federal Register Open PDF 90 FR 16441

Impact dates

  1. HHS develops and implements payment model for high-cost Medicare drugs

  2. Recommendations on Medicare Part D premium stabilization/reduction

  3. HHS publishes plan for hospital outpatient drug acquisition cost survey

  4. Medicaid drug rebate and payment innovation recommendations

  5. FDA report on accelerating generics/biosimilars and OTC reclassification

  6. HHS evaluates site-of-care payment differential regulations

  7. Labor Secretary proposes PBM fee disclosure regulations

  8. HHS/DOJ/Commerce/FTC listening sessions and anti-competitive behavior report

  9. HHS/FDA streamline drug importation program for States

  10. Condition health center grants on discounted insulin/epinephrine for low-income patients

  11. Recommendations on pharmaceutical value chain competition and PBM transparency

  12. HHS proposes Medicare Drug Price Negotiation Program guidance for 2026-2028

Market exposure

Policy exposure mapping — not investment advice. Illustrative public companies are incomplete and not recommendations.

Sectors

PharmaTechnology & software

Mechanisms

Subsidy / incentiveLicensingProcurement

Role pressure

  • MixedDomestic producer — Innovation incentives for small molecules restored but Medicare negotiation transparency and maximum fair price constraints tightened; generic/biosimilar competition accelerated
  • ProtectiveImporter — State drug importation program streamlined, creating new pathways for foreign-sourced drugs
  • AdverseDownstream manufacturer — Accelerated generic/biosimilar approvals and potential OTC reclassifications threaten brand exclusivity periods
  • UncertainEquipment supplier — Hospital outpatient drug payment may be aligned with acquisition costs, affecting pricing power

Geographies

US

Illustrative public companies

Curated watchlist matches by sector/role — incomplete; not a recommendation.

GOOGLAlphabetAAPLAppleLLYEli LillyQQQInvesco QQQ TrustJNJJohnson & JohnsonMRKMerckMETAMeta PlatformsMSFTMicrosoftNVSNovartisNVDANVIDIAORCLOraclePFEPfizerSPYSPDR S&P 500 ETF

Confidence: medium · Policy alerts

Key directives

  • HHS to propose guidance for Medicare Drug Price Negotiation Program for 2026-2028 within 60 days
  • Domestic Policy Assistant to provide Medicare Part D premium reduction recommendations within 180 days
  • HHS to work with Congress to end 'pill penalty' by aligning small molecule and biologic treatment
  • HHS to develop payment model for high-cost Medicare drugs within 1 year
  • HHS to publish plan for hospital outpatient drug acquisition cost survey within 180 days
  • OMB/Domestic Policy/Economic Policy to provide Medicaid drug rebate recommendations within 180 days
  • HHS to condition health center grants on discounted insulin/epinephrine for low-income patients within 90 days
  • Domestic Policy Assistant to provide pharmaceutical value chain recommendations within 90 days
  • FDA to issue report on accelerating generics/biosimilars and OTC reclassification within 180 days
  • HHS/FDA to streamline State drug importation program within 90 days
  • HHS to evaluate site-of-care payment regulations within 180 days
  • Labor Secretary to propose PBM fee disclosure regulations within 180 days

Who is ordered

Timeline

Immediate

  • EO signed and published; policy direction established

Near term (90d)

  • HHS to condition section 330(e) grants on discounted insulin/epinephrine practices (Sec. 7)
  • HHS/FDA to streamline drug importation program for States (Sec. 10)
  • Domestic Policy Assistant to provide recommendations on pharmaceutical value chain competition (Sec. 8)

Long term

  • HHS to propose guidance for Medicare Drug Price Negotiation Program for 2026-2028 (Sec. 3(a))
  • Recommendations to stabilize/reduce Medicare Part D premiums (Sec. 3(b))
  • HHS to develop and implement payment model for high-cost Medicare drugs (Sec. 4)
  • HHS to publish plan for hospital outpatient drug acquisition cost survey (Sec. 5)
  • Recommendations on Medicaid drug rebates and payment innovation (Sec. 6)
  • FDA report on accelerating generic/biosimilar approvals and OTC reclassification (Sec. 9)
  • HHS to evaluate/propose regulations on site-of-care payment differentials (Sec. 11)
  • Labor Secretary to propose PBM fee disclosure regulations (Sec. 12)
  • HHS/DOJ/Commerce/FTC listening sessions and report on anti-competitive behavior (Sec. 13)
  • Congressional action sought to end 'pill penalty' in Medicare negotiation (Sec. 3(c))

Risks & tensions

  • Congressional action required to end 'pill penalty' may not materialize, limiting structural change
  • 'Budget neutrality' constraints on hospital outpatient payment adjustments may blunt savings
  • Conditioning health center grants on drug pricing could face legal challenges or reduce grantee participation
  • Acceleration of generic/biosimilar approvals may trade speed for safety if not carefully implemented
  • Drug importation expansion faces practical supply chain and safety verification hurdles
  • EO characterizes IRA Medicare negotiation as 'misnamed' and producing 'much lower savings than projected'—partisan framing that may affect implementation credibility
  • Multiple 180-day deadlines create administrative burden across HHS, Labor, OMB, White House offices
Executive Order 14273: Lowering Drug Prices by Once Again Putting Americans First · Executive Orders